SEC Form 4 · accession 0001562180-16-002807
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Geno J Germano
Director
Period of report
Jul 15, 2016
Accepted (ET)
Jul 19, 2016 · 3:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to buy)F1 | $42.22 | Jul 15, 2016 | A | 20,883 | A | — | Jul 15, 2026 | Common Stock | 20,883 | 20,883 | D |
Explanation of responses
- F1The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2014 Stock Option and Incentive Plan. The option shall vest in equal monthly installments during the 36 months following the grant date, subject to continued service through such date.